<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087061</url>
  </required_header>
  <id_info>
    <org_study_id>SIGMATAU-ST-01-402</org_study_id>
    <secondary_id>UCLA-0403029-01</secondary_id>
    <secondary_id>SIGMATAU-ST-01-402</secondary_id>
    <nct_id>NCT00087061</nct_id>
  </id_info>
  <brief_title>Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma</brief_title>
  <official_title>Oral ST1481 in Adults With Malignant Glioma: A Phase I-II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gimatecan, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of gimatecan in&#xD;
      treating patients with recurrent or progressive primary malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of gimatecan in patients with recurrent or&#xD;
           progressive primary malignant glioma treated with or without concurrent enzyme-inducing&#xD;
           anticonvulsant drugs.&#xD;
&#xD;
        -  Determine whether this drug has sufficient activity to warrant further development in&#xD;
           these patients. (phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic behaviors of this drug in these patients.&#xD;
&#xD;
        -  Correlate the principal toxic effects with the pertinent pharmacokinetic parameters of&#xD;
           this drug in these patients.&#xD;
&#xD;
        -  Determine the antitumor activity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation, multicenter study. Patients are stratified&#xD;
      according to the concurrent use of enzyme-inducing anticonvulsant drugs (yes vs no).&#xD;
&#xD;
        -  Phase I: Patients receive oral gimatecan once daily on days 1-5. Courses repeat every 28&#xD;
           days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of gimatecan until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive gimatecan as in phase I at the MTD. Patients are followed for&#xD;
           at least 1 month and then every 2 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 30-83 patients (30-42 for phase I [15-21 per stratum] and&#xD;
      21-41 for phase II) will be accrued for this study within 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gimatecan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant glioma (glioblastoma multiforme, anaplastic&#xD;
             astrocytoma, or anaplastic oligodendroglioma)&#xD;
&#xD;
               -  Recurrent or progressive primary CNS neoplasm by contrast-enhanced MRI&#xD;
&#xD;
          -  Tumor progression after prior surgery, radiotherapy, or chemotherapy&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Failed prior standard curative or palliative therapy (phase I only)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 2,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGPT and SGOT ≤ 1.5 times upper limit of normal (ULN) (3 times ULN if liver metastases&#xD;
             are present)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction with the past year&#xD;
&#xD;
          -  No heart failure (including cardiac insufficiency controlled by digitalis and&#xD;
             diuretics)&#xD;
&#xD;
          -  No irreversible arrhythmias requiring permanent medication&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No gastrointestinal dysfunction that would alter absorption or motility, such as any&#xD;
             of the following:&#xD;
&#xD;
               -  Active peptic ulcer&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Known intolerance to lactose&#xD;
&#xD;
               -  Malabsorption syndromes&#xD;
&#xD;
               -  Intestinal sub-occlusion&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No mentally incapacitated patients&#xD;
&#xD;
          -  No other concurrent severe disease that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent corticosteroids allowed if dose stable for the past 2 weeks&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior surgical resection&#xD;
&#xD;
          -  No prior gastrointestinal surgery that would affect drug absorption&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior participation in any other investigational drug study&#xD;
&#xD;
          -  More than 72 hours since prior systemic antibiotics&#xD;
&#xD;
          -  No concurrent H2 antagonists, antacids, or proton pump inhibitors&#xD;
&#xD;
               -  If any of these therapies are necessary, ≥ 3 hours must elapse after gimatecan&#xD;
                  administration&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent immunosuppressive agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy F. Cloughesy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2005</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

